Pioneering Patient Adherence

Built on Nearly a Decade of Adherence Innovation

PACE Clinical did not emerge in isolation.

Its foundation was established within Link2Trials beginning in 2017, where early behavioral adherence modeling was integrated into recruitment workflows.

As the Adherence Risk Management (ARM) methodology matured, its strategic importance became clear.

Through active participation in the EU-funded BEAMER project (IMI2 / EFPIA under Horizon 2020), our team contributed to the development of advanced computational adherence modeling frameworks.

Over time, adherence risk management evolved from a component of broader services into a dedicated discipline.

PACE Clinical was established to focus exclusively on advancing this field.

This evolution reflects continuity, not reinvention.

From Engagement to Behavioral Intelligence

For years, adherence initiatives centered on communication and reminders.

Our work introduced a different approach:

Understanding the behavioral drivers behind adherence decisions.

Beginning in 2017, we began integrating structured behavioral modeling into patient recruitment recruitment workflows.

This led to:

• Development of the ARM methodology
• Digital support pathways tailored to individual patient drivers
• Risk-based adherence profiling
• Early intervention logic within trial operations

Through collaboration with academic partners and European innovation programs, adherence moved from reactive engagement toward predictive risk intelligence.

PACE Clinical continues to advance this discipline.

Advancing Adherence Through European Collaboration

Since 2021, our team has been actively involved in the BEAMER project.

BEAMER is supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under grant agreement No 101034369 of the Horizon 2020 program.

The project focuses on understanding and improving patient adherence across healthcare settings through advanced behavioral modeling.

A central outcome of BEAMER is the B-COMPASS computational model, which enhances prediction of adherence behavior by integrating:

• Health consciousness
• Personal concerns
• Treatment priorities
• Contextual influences

The insights generated within BEAMER are integrated into the ARM platform.

This ensures that our solutions remain scientifically validated, continuously evolving, and aligned with European research standards.

Beamer partners: